Last updated: August 1, 2026
Propine, the brand name for dipivefrin hydrochloride ophthalmic solution 0.1%, is a legacy glaucoma medicine with limited or no current U.S. commercial activity. The product was developed as a prodrug of epinephrine for ocular hypertension and open-angle glaucoma. Its commercial position declined as beta blockers, topical carbonic anhydrase inhibitors, alpha agonists, and prostaglandin analogs became standard therapies. No current public evidence indicates a meaningful U.S. revenue stream, active Orange Book protection, pending Paragraph IV litigation, or a viable branded-market exclusivity position for Propine.
What is Propine and what was it used for?
Propine contains dipivefrin hydrochloride, a lipophilic prodrug converted in ocular tissues to epinephrine. It was marketed as a 0.1% ophthalmic solution for reducing elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.[1]
| Attribute |
Propine |
| Active ingredient |
Dipivefrin hydrochloride |
| Dosage form |
Sterile ophthalmic solution |
| Strength |
0.1% |
| Therapeutic area |
Glaucoma and ocular hypertension |
| Pharmacologic concept |
Prodrug converted to epinephrine |
| Original commercial positioning |
Topical adrenergic pressure-lowering therapy |
| Current U.S. commercial status |
Legacy or discontinued product status |
| Current branded exclusivity |
No apparent active exclusivity |
| Biosimilar relevance |
None; Propine is a small-molecule ophthalmic drug |
Dipivefrin was designed to improve corneal penetration compared with epinephrine. Once converted to epinephrine, it reduces intraocular pressure through effects on aqueous humor production and outflow. The product’s clinical utility was limited by the broader tolerability and convenience advantages of newer glaucoma treatments.[1][2]
When did Propine lose market exclusivity?
Propine’s core composition and use patents are historical and are not understood to provide active U.S. market exclusivity. The product was introduced decades ago, placing any original patent protection well beyond the standard U.S. patent term applicable to modern pharmaceutical patents.
For a drug first developed and commercialized in the 1970s or earlier, the relevant product patents would ordinarily have expired many years ago, subject to the patent law and regulatory framework in effect at the time. No current patent term extension or pediatric exclusivity appears to support Propine.
Propine exclusivity timeline
| Event |
Market implication |
| Original dipivefrin development |
Established the product’s historical patent and regulatory position |
| FDA approval and commercialization |
Created branded prescription-market access |
| Expansion of glaucoma alternatives |
Reduced clinical differentiation |
| Expiration of historical patents |
Removed composition and basic use exclusivity |
| Declining commercial availability |
Reduced incentive for manufacturers to maintain supply |
| Current status |
No apparent active branded exclusivity in the U.S. |
The commercial issue is therefore not an approaching loss of exclusivity. Propine’s exclusivity period has already ended, and the product’s market appears to have contracted primarily because of therapeutic substitution and weak commercial demand.
What is the FDA regulatory status of Propine?
Propine is not a current growth product in the U.S. prescription market. FDA product databases and labeling records identify dipivefrin ophthalmic solution as an established product with historical approval and discontinued or inactive commercial status.[3][4]
A discontinued listing does not, by itself, establish that FDA withdrew the product for safety or efficacy reasons. Products may leave the market because of low demand, manufacturing economics, supply problems, portfolio rationalization, or commercial discontinuation. The available regulatory record supports a legacy-product interpretation rather than a recent FDA safety withdrawal.
Is Propine still marketed in the United States?
The product has limited practical U.S. availability. Current commercial access may depend on residual inventory, historical listings, specialty sourcing, or alternative international supply. A prescription listing in a reference database does not establish active manufacturer distribution.
The relevant distinction is:
- FDA approval history: historical.
- Current commercial availability: limited or absent.
- Current branded promotion: not evident.
- Active exclusivity: not evident.
- Current market growth: not evident.
What patents protect Propine?
No active U.S. patent estate appears to protect Propine as a commercial product. The principal intellectual-property categories historically associated with dipivefrin would have included:
- Dipivefrin composition patents.
- Ophthalmic formulation patents.
- Methods of lowering intraocular pressure.
- Manufacturing processes for preparing the prodrug or ophthalmic solution.
Those rights are historical. The age of the product means that any relevant U.S. patent protection would generally have expired before the current period.
Are there active formulation patents for Propine?
No commercially material active formulation patent position is apparent. Propine’s dosage form is a conventional ophthalmic solution rather than a modern sustained-release implant, depot formulation, nanoparticle system, or device-integrated delivery platform.
The product’s formulation barriers were therefore modest compared with newer ophthalmic products protected by:
- Preservative-free delivery systems.
- Multidose container technology.
- Sustained-release ocular inserts.
- Combination products.
- Specialized suspensions or emulsions.
- Drug-device delivery systems.
A manufacturer seeking to reintroduce dipivefrin would likely face formulation-development and manufacturing requirements, but those requirements would not necessarily create patent-based exclusivity.
How many patents cover Propine?
There is no apparent active U.S. patent family that currently provides meaningful market protection for Propine. Historical patent records may contain multiple documents relating to dipivefrin, epinephrine derivatives, ophthalmic compositions, or glaucoma treatment methods. The existence of historical patents does not create current blocking rights after expiration.
| Patent category |
Current commercial significance |
| Dipivefrin composition |
Historical; expected to be expired |
| Ophthalmic solution |
Historical unless a later, independently protected formulation exists |
| Method of treating glaucoma |
Historical and generally vulnerable to expiration or design-around |
| Manufacturing process |
Potentially relevant to know-how, but no apparent active market barrier |
| Device or delivery system |
Not central to the original Propine product |
A definitive live-patent count would require a current family-level search across U.S. and foreign registers. The commercially relevant conclusion is that no active Propine patent estate is visible in the public record.
Are there Paragraph IV challenges or Propine patent lawsuits?
No material recent Paragraph IV litigation involving Propine is apparent. Paragraph IV litigation is most relevant when an approved drug has listed patents in the FDA Orange Book and a generic applicant challenges those patents before launch.
Propine does not appear to have a current Orange Book patent dispute comparable to litigation involving high-value branded ophthalmic products. There is no known active settlement agreement that controls generic entry for dipivefrin.
Orange Book status
| Question |
Assessment |
| Current listed Propine patents |
No material active listing apparent |
| Recent Paragraph IV notices |
No material public activity identified |
| Active patent litigation |
No material recent case apparent |
| Generic-entry settlement |
No material public settlement identified |
| Exclusivity blocker |
None apparent |
The absence of Paragraph IV litigation does not indicate that generic competition was legally defeated. It indicates that the product’s commercial scale and remaining patent value were insufficient to generate the typical litigation pattern associated with major branded drugs.
What is the financial trajectory for Propine?
Propine does not have a separately reported current revenue stream in public-company filings. Historical sales figures are difficult to isolate because the product was part of ophthalmology portfolios that included multiple glaucoma and ocular-care products.
Its financial trajectory can be summarized as follows:
| Period |
Financial condition |
| Early commercialization |
Supported by unmet demand for topical pressure-lowering therapy |
| Mature branded period |
Faced competition from established glaucoma medicines |
| Post-patent period |
Lost pricing power and differentiation |
| Later commercial period |
Likely affected by declining prescriptions and manufacturing economics |
| Current period |
No visible material branded revenue exposure |
The principal financial drivers were therapeutic substitution and portfolio economics rather than patent expiry alone. Prostaglandin analogs such as latanoprost offered strong pressure reduction and convenient dosing. Timolol and other established agents had broad physician familiarity. Combination products also reduced the commercial need for older adrenergic agents.
A company considering reintroduction would need to evaluate:
- Manufacturing cost for sterile ophthalmic production.
- Preservative and container requirements.
- FDA regulatory maintenance costs.
- Distribution economics.
- Reimbursement and pharmacy access.
- Clinical demand among patients unable to tolerate newer agents.
- Competition from low-cost generic glaucoma medicines.
Without a differentiated formulation, device, or clinical niche, the addressable market would likely be narrow.
How does Propine compare with current glaucoma therapies?
Propine is commercially disadvantaged against modern first-line treatments.
| Product class |
Typical commercial advantage over Propine |
| Prostaglandin analogs |
Strong efficacy, once-daily dosing, broad use |
| Beta blockers |
Low-cost generic availability and extensive physician familiarity |
| Alpha agonists |
Established role in pressure reduction and combination therapy |
| Carbonic anhydrase inhibitors |
Multiple generic options and combination products |
| Fixed-dose combinations |
Lower treatment burden |
| Sustained-release products |
Delivery differentiation and adherence benefits |
Dipivefrin may retain clinical relevance in limited cases, but the product lacks the commercial features that support premium pricing. Its prodrug design offers historical pharmacologic interest, yet it does not provide a clear present-day advantage over widely available alternatives.
What generic entry risks exist for Propine?
Generic entry risk is technically high but commercially muted. The basic active ingredient and conventional ophthalmic solution are old, and no apparent active patent estate blocks competition.
The main barriers are regulatory and operational:
- Demonstrating pharmaceutical equivalence.
- Establishing product quality and stability.
- Meeting sterile manufacturing requirements.
- Securing an approved manufacturing site.
- Maintaining reliable supply of ophthalmic packaging.
- Achieving sufficient volume to justify commercialization.
A generic applicant would face limited patent risk but uncertain market economics. The likely outcome is not a major branded-to-generic revenue transfer. It is a small, low-margin market in which manufacturers may choose not to enter or may discontinue the product if demand is inadequate.
Are there biosimilar risks for Propine?
Biosimilar risk is irrelevant because Propine contains dipivefrin, a chemically synthesized small molecule. Any competitive product would follow a generic-drug pathway rather than the biosimilar pathway.
The relevant FDA regulatory route would generally involve an abbreviated new drug application if a reference product and applicable requirements were available. The principal issues would involve pharmaceutical equivalence, bioequivalence or other FDA-accepted comparative requirements, and ophthalmic product quality.[5]
What licensing deals affect Propine?
No major current licensing transaction involving Propine is apparent in public company disclosures. Historical development or commercialization rights may have changed hands as ophthalmology portfolios were consolidated, but Propine is not identified as a material current licensing asset in major pharmaceutical transaction reporting.
The absence of visible licensing activity is consistent with:
- Expired core intellectual property.
- Low expected market size.
- Availability of competing glaucoma products.
- Limited pricing power.
- Commercial discontinuation or inactivity.
A future transaction would likely be structured around an asset acquisition, discontinued-product revival, or regional commercialization right rather than a high-value global license.
What geographic markets may still support dipivefrin?
Any residual demand is more likely to occur in markets where:
- Generic glaucoma treatment access is uneven.
- Older ophthalmic products remain clinically familiar.
- Local manufacturers maintain legacy products.
- Regulatory requirements permit continued distribution of established formulations.
The U.S. market appears commercially weak. Foreign availability cannot be inferred from historical U.S. approval records, and local registration, supply, and patent status would need to be assessed separately by country.
Geographic patent coverage is unlikely to create a major barrier for the original active ingredient because of the product’s age. The more relevant constraints are local regulatory registration, sterile manufacturing capacity, and distribution.
How strong is the Propine patent estate?
Propine has a weak current patent estate.
| Factor |
Assessment |
| Composition protection |
Expired or historical |
| Formulation protection |
No material active protection apparent |
| Method-of-use protection |
Historical and likely expired |
| Patent litigation exposure |
Low |
| Generic entry barrier |
Low from an IP perspective |
| Manufacturing barrier |
Moderate because of sterile ophthalmic requirements |
| Commercial differentiation |
Low |
| Reinvestment case |
Weak without a new formulation or delivery platform |
The strongest remaining barriers are operational, not legal. A company could potentially create new patent value through a novel preservative-free formulation, sustained-release system, combination product, or drug-device platform. That would be a new product-development program rather than a revival of legacy Propine exclusivity.
Key Takeaways
- Propine is dipivefrin hydrochloride ophthalmic solution 0.1%, a legacy treatment for open-angle glaucoma and ocular hypertension.
- The product has no apparent current U.S. commercial growth platform.
- Historical composition, formulation, and use patents are not expected to provide active market exclusivity.
- No material recent Paragraph IV litigation, Orange Book patent dispute, or generic settlement is apparent.
- Biosimilar competition is irrelevant because dipivefrin is a small molecule.
- The financial trajectory was shaped by therapeutic substitution, generic competition, and declining commercial demand.
- Any future opportunity would depend on a differentiated formulation, delivery system, or narrowly defined clinical niche.
- Manufacturing and regulatory maintenance are more significant barriers than patent rights.
FAQs About Propine Patent and Market Status
Is Propine still available by prescription?
Propine has limited or absent current U.S. commercial availability. Historical approval and labeling records do not establish active distribution.
What is the generic name for Propine?
The generic name is dipivefrin hydrochloride ophthalmic solution, commonly supplied at a 0.1% strength.
Does Propine have an Orange Book patent?
No material active Orange Book patent protection is apparent for Propine.
Can a generic company launch dipivefrin?
A generic company would face low apparent patent risk but would still need to satisfy FDA requirements for a sterile ophthalmic product and demonstrate commercially sustainable demand.
Why did Propine decline commercially?
Propine lost share to prostaglandin analogs, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and fixed-dose combinations that offered stronger market access, broader physician adoption, convenient dosing, or lower cost.
References
- DailyMed. (n.d.). Propine: Dipivefrin hydrochloride ophthalmic solution, 0.1% prescribing information. U.S. National Library of Medicine.
- American Academy of Ophthalmology. (n.d.). Primary open-angle glaucoma preferred practice pattern. American Academy of Ophthalmology.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process and generic drug requirements.
